NECTAR 2022

32nd Annual meeting
of the Network for European CNS
Transplantation and Restoration

nectar-athens22.gr

24-26
OCTOBER
2022

ATHENS GREECE · COTSEN HALL

PROGRAMME

Monday
24/10

12:00- Registration

13:15-13:30 Opening - Welcome

13:30-14:30 Plenary I

Nissim Benvenisty, *The Azrieli Center for Stem Cells and Genetic Research, The Hebrew University of Jerusalem, Israel*
The Essentialome of Human Development and Disease

14:30-16:00 Session 1
Clinical trials

Tilo Kunath, *Institute for Stem Cell Research, University of Edinburgh, UK*
Tool kit for dopaminergic progenitor cell production

Jun Takahashi, *CiRA-Kyoto University, Japan*
R&D of iPS cell-based therapy for stroke

Steven Goldman*, Centre for Translational Neuromedicine, University of Rochester & University of Copenhagen Faculty of Health and Medical Sciences, Denmark*
Challenges towards clinical translation of cell therapies for Huntington's disease

16:00-16:30   Coffee

16:30-18:30 Session 2
Advances in CNS disease modeling

Jens Schwamborn, *Luxembourg Centre for Systems Biomedicine, Luxembourg*
Modeling Parkinson's disease with human midbrain organoids

Achille Gravanis, *School of Medicine University of Crete & Institute of Molecular Biology and Biotechnology, Crete, Greece*
Designing brain-on-chip platforms for simulating human brain function and malfunction

Evangelos Kiskinis, *Feinberg School of Medicine, Northwestern University, Chicago USA*
Artificial Extracellular Matrix Scaffolds Enhance Maturation and Ageing of Human Stem Cell-Derived Neurons and Enable the Modeling of Neurodegenerative Disease Pathology

Alessandro Fiorenzano, *Lund Stem Cell Center, Sweden*
Modeling dopamine neuron specification and diversity using human stem cell-based technologies

18:30-19:30 Plenary II

Lee Rubin, *Harvard Stem Cell Institute, USA*
Disease modeling and phenotypic drug screening

19:30 Welcome Reception

Tuesday
25/10

09:00-11:00 Session 3
Neuroinflammation and glial cells in neurodegenerative diseases

Malú Gámez Tansey, *Center for Translational Research in Neurodegenerative Disease, University of Florida College of Medicine, Gainesville, USA*
Inflammation and immune dysfunction in Parkinson disease

Stefano Plucino, *Dept of Clinical Neurosciences, University of Cambridge, UK*
Molecular fuels and drivers of smouldering disease in progressive multiple sclerosis

Jari Koistinaho, *Neuroscience Center, Helsinki Institute of Life Science HiLIFE, Finland*
Modelling the impact of glial cells in Alzheimer disease and schizophrenia by iPSC-derived cells

Era Taoufik, *Hellenic Pasteur Institute, Athens, Greece*
Neuroinflammation and astrocytes in Parkinson disease

11:00-11:25 Coffee

11:25-12:10 Data Blitz session I: Oral presentations (7)

12:10-13:00 Plenary III

Ido Amit, *Weizmann Institute of Science, Israel*
The power of ONE: Immunology in the age of single cell genomics

13:00-14:00 Lunch

14:00-16:00 Session 4
Preclinical cell/gene therapies in neurological disorders I

Olivier Goureau, *Institut de la Vision, Sorbonne Université, INSERM, CNRS Paris, France*
Pluripotent stem cell-based therapy for outer retinal diseases

Tuesday
25/10

Sandro Alves, *BrainVectis - Askbio, Institut du Cerveau (ICM), Paris, France*
Restoration of brain cholesterol metabolism as gene therapy approach for Huntington's Disease

Luís Pereira de Almeida, *Center for Neuroscience and Cell Biology, University of Coimbra, Portugal*
Therapeutic strategies for spinocerebellar ataxia type 3

Dimitra Thomaidou, *Hellenic Pasteur Institute, Greece*
Direct astrocyte to neuron reprograming: towards a therapeutic strategy for brain injuries

16:00-16:35 Data Blitz session II: Oral presentations   (6)

16:35-17:00   Coffee

17:00-18:00 Special Session
Patient Advocacy

Benjamin Stecher, *Chair of the Patient Advisory Board (PAB), Rune Labs, San Francisco, USA*
What Patient Advocacy Can Do

18:00-20:00 Session 5
Preclinical cell/gene therapies in neurological disorders II

Malin Parmar, *Wallenberg Neuroscience Center & Lund Stem Cell Center, Sweden*
Reprogramming as a regenerative therapy in Parkinson Disease

Sabah Mozafari, *ICM Paris, Sorbonne University France*
Potential of Multiple Sclerosis iPSC-derived oligodendroglia to functionally interact with axons and glia in vivo

Clive Svendsen, *Cedars-Sinai Regenerative Medicine Institute, Los Angeles, USA*
Stem cell therapies for amyotrophic lateral sclerosis

Mark Tuszynski, *University of California San Diego, USA*
Neural Stem Cell Therapy for Spinal Cord Injury

21:00   Conference Dinner

Wednesday
26 /10

9:00 - 09:30 Data Blitz session III: Oral presentations (5)

09:30 – 10:30 Session 6
Companies/Biotech

XONA MICROFLUIDICS
Ann Taylor, *Chief Scientific Officer, Xona Microfluidics, Inc., USA*

Novo NORDISK
How to bring cell therapy from research to patients?
Good collaboration between academia and pharma companies can be the key for bringing cell therapy from research to patients
Ida Stenfeldt Mathiasen, *Project Director Clinical Pharmacology*
Anne Møller Nielsen, *MD, PhD, International Medical Director*

AXOL Biosciences
HiPSC derived Microglia-like cells as a model for Neurodegenerative diseases
Vijitha Sathiaseelan

10:30-11:00 Data Blitz session IV: Oral presentations (5)

11:00-11:30 Coffee

11:30-13:30 Session 7
Disease mechanisms

Frederic Saudou, *Institut Neurosciences, Grenoble, France*
Molecular mechanisms in Huntington's disease

Magdalini Polymenidou*, University of Zurich, Switzerland*
RNA-RBP interactions/ phase separation in neurodegenerative diseases

Chiara Zurzolo, *Institut Pasteur, Paris, France*
Disease spreading through tunneling nanotubes

Maria Xylouri, *Biomedical Research Foundation of the Academy of Athens, Greece*
Multiple systems atrophy

13:30-14:00 Closing remarks - Departure